Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)

Trial Profile

Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary)
  • Indications Hepatitis A
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Nov 2015 Status changed from Not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 15 Aug 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 11 Aug 2014 New source identified and integrated (European Clinical Trials Database record:EudraCT2013-001918-15 ).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top